Marker Therapeutics Inc (MRKR)

[Phantom Lord]

Got a reply back. Lymphoma is high on their radar and they are motivated to advance the lymphoma trial given what they have seen so far. Right now the biggest hiccup is finding a trial design that will allow them to sufficiently accrue patients. With the approval of Yescarta the key opinion leaders are worried that it will take a majority of the patients given that it is an approved therapy. If this does happen then Marker would need to focus on CAR-refractory patients or in a subgroup of lymphoma without an approved therapy like mantle cell. The bright side for Marker is that it seems like most patients are not getting Yescarta partly due to costs and reimbursement issues. They are continuing to asses what the right trial design will be for lymphoma given the above information.